Veenat 100 mg is an oral tablet of imatinib mesylate, a selective tyrosine kinase inhibitor that targets BCR‑ABL, c‑KIT, and PDGFR. It’s used in adult patients with chronic myeloid leukemia (CML), Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL), and c‑KIT positive gastrointestinal stromal tumors (GIST). By inhibiting these disease-driving kinases, Veenat helps control malignant cell growth and supports long-term disease management.
Select options
This product has multiple variants. The options may be chosen on the product page
Lenalid 5 mg is a low-dose oral capsule containing Lenalidomide, used to manage and treat multiple myeloma, myelodysplastic syndromes (MDS), and certain lymphomas. It works by enhancing immune activity and reducing abnormal cancer cell growth. This lower dose is often prescribed for patients needing milder therapy or as part of a long-term maintenance treatment strategy.
Select options
This product has multiple variants. The options may be chosen on the product page
Veenat 400 mg is a high-dose oral tablet of imatinib mesylate—a targeted tyrosine kinase inhibitor that selectively inhibits BCR‑ABL, c‑KIT, and PDGFR. Designed for adult patients with advanced, resistant, or high-burden disease, it is approved for chronic myeloid leukemia (CML), Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL), and c‑KIT positive gastrointestinal stromal tumors (GIST). Higher drug exposure helps overcome resistance and maintain remission in challenging cases.
Select options
This product has multiple variants. The options may be chosen on the product page
Xarelto 20 mg is an oral tablet containing rivaroxaban, a direct factor Xa inhibitor. It’s prescribed to prevent stroke and systemic embolism in non-valvular atrial fibrillation, treat and prevent recurrence of deep vein thrombosis (DVT) and pulmonary embolism (PE), and reduce clot risk after hip or knee replacement surgery.
Select options
This product has multiple variants. The options may be chosen on the product page
Xovoltib 20 mg is an oral tablet containing afatinib dimaleate, a second-generation irreversible tyrosine kinase inhibitor targeting EGFR (including common and uncommon mutations) and HER2 receptors. It is primarily used for patients with advanced or metastatic non‑small cell lung cancer (NSCLC) harboring activating EGFR mutations (like L858R or exon 19 deletion), and may also have efficacy in certain HER2-positive or other solid tumor contexts.
By blocking key signaling pathways, Xovoltib helps suppress tumor growth and can delay disease progression, especially in molecularly defined cancer subtypes.
Select options
This product has multiple variants. The options may be chosen on the product page
Xovoltib 30 mg is an oral tablet delivering afatinib dimaleate, a second-generation irreversible inhibitor of EGFR and HER2 tyrosine kinases. Designed for patients with advanced or metastatic non‑small cell lung cancer (NSCLC) that harbor activating EGFR mutations, including L858R and exon 19 deletion, or certain HER2-positive tumors. It improves tumor control by blocking key signaling pathways driving cancer growth.
Select options
This product has multiple variants. The options may be chosen on the product page
Xovoltib 40 mg is an oral afatinib dimaleate tablet offering a powerful, irreversible inhibition of EGFR and HER2 tyrosine kinases. It is used for advanced or metastatic non‑small cell lung cancer (NSCLC) driven by activating EGFR mutations, and may benefit select HER2-positive cases. As the highest commonly available dose, it supports potent systemic therapy where lower doses are insufficient or disease-resistant
Select options
This product has multiple variants. The options may be chosen on the product page
Xovoltib 50 mg contains afatinib dimaleate, a second-generation, irreversible tyrosine kinase inhibitor targeting EGFR and HER2 receptors. Designed for patients with advanced or metastatic non‑small cell lung cancer (NSCLC) driven by activating EGFR mutations, this 50 mg dose offers intensified exposure for individuals who require potent systemic therapy beyond lower dose options.
Select options
This product has multiple variants. The options may be chosen on the product page
Xpreza 100 mg is an oral tablet formulation of esomeprazole magnesium, a proton pump inhibitor (PPI) that suppresses gastric acid secretion. It is prescribed for treating gastroesophageal reflux disease (GERD), erosive esophagitis, Zollinger–Ellison syndrome, and peptic ulcer disease. Extended acid suppression supports symptom relief and mucosal healing.
Select options
This product has multiple variants. The options may be chosen on the product page
Xtane 25 mg is an oral tablet containing tamsulosin hydrochloride, a selective alpha‑1 adrenergic receptor antagonist. It relaxes muscles in the prostate and bladder neck, improving urinary flow and reducing BPH symptoms such as urgency, frequency, and incomplete emptying.
Select options
This product has multiple variants. The options may be chosen on the product page
End of content
End of content
Join our newsletter and get 20% off your first order
Subscribe to our newsletter and get the latest trending products and offers updates.
Wait! before you leave…
We have something special for you
Use above code to get 20% off for your first order when checkout. Don't miss it.
In order to provide you a personalized shopping experience, our site uses cookies. By continuing to use this site, you are agreeing to our cookie policy.
